Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT03583528
Overview
Neuroendocrine tumours (NETs) are generally slow growing, but some can be aggressive and resistant to treatment. Compared to healthy cells, the surface of these tumor cells has a greater number of special molecules called somatostatin receptors (SSTR). Somatostatin receptor scintigraphy and conventional imaging are used to detect NETs. This study proposes 68Gallium(68Ga)-DOTATOC positron emission tomography/computed tomography (PET/CT) is superior to current imaging techniques. The goal is to evaluate the safety and sensitivity of 68Ga-DOTATOC PET/CT at detecting NETs and other tumors with over-expression of somatostatin receptors.
Sponsor
British Columbia Cancer Agency
Phase
N/A
Contacts
Heather Saprunoff
hsaprunoff@bccancer.bc.ca
604-877-6000 ext 2818
ClinicalTrials.gov
NCT03583528Drug / Compound
Help us improve your experience